| 0.73 0.02 (2.8%) | 12-01 15:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.91 | 1-year : | 1.01 |
| Resists | First : | 0.78 | Second : | 0.87 |
| Pivot price | 0.71  |
|||
| Supports | First : | 0.64 | Second : | 0.54 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.7 |
| MA(100) : | 0.93  |
MA(250) : | 1.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.5 |
D(3) : | 45.6 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 1.92 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ QLGN ] has closed below upper band by 22.3%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.74 | 0.74 - 0.74 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.72 - 0.73 | 0.73 - 0.74 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Mon, 27 Nov 2023
QLGN: Dosing Begins in Phase 1 Trial of QN-302… - Yahoo Finance
Tue, 14 Nov 2023
Qualigen Therapeutics Provides Corporate Update for Third Quarter ... - GlobeNewswire
Tue, 07 Nov 2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase ... - BioSpace
Wed, 27 Sep 2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR ... - Yahoo Finance
Tue, 15 Aug 2023
Qualigen Therapeutics, Inc. Reports Financial Results and ... - BioSpace
Tue, 01 Aug 2023
Qualigen Therapeutics Announces US FDA IND Clearance to ... - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | -4.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.32 |
| Profit Margin | 0 % |
| Operating Margin | -314.1 % |
| Return on Assets (ttm) | -71.8 % |
| Return on Equity (ttm) | -290.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.96 |
| EBITDA (p.s.) | -2.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | -2.29 |
| Price to Sales | 0.75 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|